Briefing
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
Retrospective exploratory analysis of TP53-mutant ctDNA as a treatment-response biomarker in relapsed high-grade serous ovarian carcinoma.
- Design: Evidence level 3
- Assay: Not named in the abstract